EUVIMED · CrossrefJournal
JAMA Cardiology
ISSN 2380-6583 · American Medical Association (AMA)
Latest articles
Effect of Acoramidis on Heart Failure–Related Health Status
Effect of Acoramidis on Heart Failure–Related Health Status
Effect of Acoramidis on Heart Failure-Related Health Status—Reply
Anemia and Iron Status in Pregnant and Postpartum Women With Acute Heart Failure
Residual Peridevice Leak at 45-Day Transesophageal Echocardiogram After Left Atrial Appendage Occlusion
Sex Differences in Quantified Mitral Regurgitation
Sex Differences in Quantified Mitral Regurgitation—Reply
Aging Populations and the Rising Burden of Cardiovascular Disease
First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes
Assessment of Coronary Inflammatory Risk From Noncontrast Cardiac Computed Tomography
AI-Identified Reasons for Nonescalation of Lipid-Lowering Therapy for Secondary Prevention
Ebstein Anomaly With Pre-excited Atrial Fibrillation
Man in His 20s With A New Rash and Right Atrial Mass
Threshold Optimization Vs Assay Advancement
Threshold Optimization Vs Assay Advancement
Threshold Optimization Vs Assay Advancement
Threshold Optimization Vs Assay Advancement—Reply
Efficacy and Safety of Routine Postdilation in Balloon-Expandable Transcatheter Aortic Valve Implantation Platform
Routine Postdilation to Optimize Balloon-Expandable Valve Expansion
Atrial Pseudomasses in Erdheim-Chester Disease
Dynamic Mitral Obstruction by a Left-Sided Cardiac Sarcoma
The Future of Genetic Therapy for Inherited Cardiomyopathy
Remote Detection of Cardiac Implantable Electrical Devices
An Axillary Mass in Pulmonary Embolism
Pooled Prasugrel Doses in a P2Y12 Network Meta-Analysis
Pooled Prasugrel Doses in a P2Y12 Network Meta-Analysis—Reply
Undiagnosed Chronic Kidney Disease, Outcomes, and Finerenone in Heart Failure
Interpreting 7-Year Valve Durability in PARTNER 3
Interpreting 7-Year Valve Durability in PARTNER 3
EUVIMED